House dust (1-3)-beta-D-glucan and wheezing in infants

Y Y Iossifova1, T Reponen, D I Bernstein

  • 1Department of Environmental Health, University of Cincinnati, Cincinnati, OH 45267-0056, USA.

Allergy
|April 20, 2007
PubMed
Abstract

Insights

High indoor exposure to (1-3)-beta-D-glucan may protect infants from wheezing and allergen sensitization. This fungal component showed a reduced risk for recurrent wheezing, especially in allergen-sensitized infants.

Area of Science:

  • Environmental health
  • Pediatric allergy
  • Mycology

Background:

  • Fungal (1-3)-beta-D-glucan is linked to adult respiratory issues.
  • Limited data exists on infant exposure and health effects.
  • This study investigates (1-3)-beta-D-glucan's impact on infant wheezing and sensitization.

Purpose of the Study:

  • To determine the association between indoor (1-3)-beta-D-glucan exposure and infant wheezing.
  • To assess the link between (1-3)-beta-D-glucan exposure and allergen sensitization in infants.
  • To explore the role of endotoxin as a potential confounder.

Main Methods:

  • A birth cohort of 574 infants born to atopic parents was studied.
  • (1-3)-Beta-D-glucan and endotoxin levels were measured in settled dust.
  • Outcomes included parental reports of wheezing and skin prick testing for sensitization at age one.

Main Results:

  • High (1-3)-beta-D-glucan exposure was associated with reduced wheezing (aOR=0.39) and combined wheezing/sensitization (aOR=0.13).
  • A trend towards reduced sensitization was observed with higher (1-3)-beta-D-glucan levels (aOR=0.57).
  • Low (1-3)-beta-D-glucan exposure correlated with increased wheezing risk.

Conclusions:

  • High indoor (1-3)-beta-D-glucan levels (>60 microg/g) may decrease recurrent wheezing risk in infants from atopic families.
  • This protective effect is more significant in allergen-sensitized infants.
  • No significant associations were found between endotoxin exposure and the studied health outcomes.

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Allergic Reactions02:06

Allergic Reactions

Overview
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma